Freeline Therapeutics: Guggenheim initiates with "buy" on promising pipeline
06/05/2021 13:04
** Guggenheim starts coverage of gene therapy co, Freeline
Therapeutics Holdings plc FRLN.O , with a "buy" rating and a
$17 PT
** Brokerage's PT represents a premium of 51.1% to FRLN's
last close
** Brokerage sees limited market opportunity for FLT180a,
co's gene therapy candidate for blood clotting disorder
hemophilia B, but is optimistic about the potential of co's
experimental treatments for inherited disorders Fabry and
Gaucher's disease
** Says a successful execution of co's dose-finding study of
FLT180a would provide a robust foundation for the Fabry and
Gaucher's disease treatments- FLT190 and FLT201
** Expects FLT190 for Fabry disease to be a significant
value driver for FRLN during 2022
** With stock trading lower than peer group, "we would be
opportunistic buyers heading into 2022" - Guggenheim
** Stock is down 38.4% YTD as of its last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))